

Investment Opportunities in APIs-KSMs-Drug Intermediates Bulk Drug Industries.

Description:

Investment Opportunities in APIs-KSMs-Drug Intermediates Bulk Drug Industries. Cabinet Approves Promotion of Domestic Manufacturing of Critical Key Starting Materials-Drug Intermediates and Active Pharmaceutical Ingredients in the Country.

Key Starting Materials (KSMs)/[Drug Intermediates](#)

KSMs from the [essential](#) medicines list for strategic reasons posed by the COVID-19.

Role of Government towards (KSMs)/[Drug Intermediates](#)

The Union Cabinet chaired by the Prime Minister, Shri Narendra Modi has approved the following schemes:

The scheme on Promotion of [Bulk Drug](#) Parks for financing Common Infrastructure Facilities in 3 Bulk Drug Parks with financial implication of Rs. 3,000 crore for next five years.

Production Linked Incentive (PLI) Scheme for promotion of domestic manufacturing of critical KSMs/[Drug Intermediates and APIs](#) in the country with financial implications of Rs 6,940 crore for next eight years.

Keywords: #Levofloxacin #Sulfadiazine #Ciprofloxacin #Ofloxacin #Norfloxacin #Artesunate #Telmisartan #Losartan #Valsartan #Olmesartan #Atorvastatin #Acyclovir #Lopinavir #Ritonavir #Oxcarbazepine #Carbamazepine #Levodopa #Carbidopa #Levetiracetam #Aspirin #Diclofenac Sodium #Tinidazole #Ornidazole #businessopportunity #projectreport #DetailedProjectReport #businessconsultant #businessfeasibilityreport #BusinessPlan #startyourbusiness #investmentopportunity #growyourbusiness #startups #business #covidbu

Created At: 15 Jun, 2020